Stockwinners Market Radar for January 24, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:05 EST BANGL JV adds Rattler Midstream as strategic partner - WhiteWater Midstream, MPLX LP (MPLX), and West Texas Gas announced the addition of a fourth partner, Rattler Midstream LP (RTLR), to the companies' BANGL, LLC joint venture. Concurrent with Rattler's investment in the project, Diamondback Energy, Inc. (FANG), Rattler's upstream operating parent, entered into a significant, long-term natural gas liquids product dedication with BANGL. BANGL began full commercial service in the fourth quarter of 2021 and provides NGL takeaway capacity from MPLX and WTG gas processing plants in the Permian Basin to the NGL fractionation hub in Sweeny, Texas. WhiteWater's investment in BANGL is backed by Ridgemont Equity Partners, Denham Capital Management and the Ontario Power Generation Inc. Pension Plan. BANGL is a joint venture between White Water, MPLX, WTG, and Rattler. The natural gas liquids pipeline system connects the Delaware and Midland basins of Texas to the fractionation market in Sweeny, Texas and has expansion capacity of up to 300,000 barrels per day.

17:37 EST IBM sees FY22 free cash flow $10B-$10.5B - Says seeing progress in software growth rate. Says has solid momentum in IBM consulting revenue. Says expects mid- to high-teens tax rate in FY22. Says had solid revenue performance. Says increasing investments in research and development. Says strong market demand for automation. Says laser-focused on hybrid cloud and AI strategy. Says currency dynamic will be a headwind. Comments taken from Q4 earnings conference call.

17:14 EST Deciphera presents Phase 3 results of ripretinib in gastrointestinal tumor - Deciphera presented results from the INTRIGUE Phase 3 study of Qinlock, or ripretinib, in patients with gastrointestinal stromal tumor previously treated with imatinib at the American Society of Clinical Oncology Plenary Series Session. Although the INTRIGUE study did not meet its primary endpoint of superiority in progression-free survival versus sunitinib, the efficacy of ripretinib appears comparable to sunitinib in 2nd line patients. In addition, ripretinib had a more favorable safety profile than sunitinib with fewer Grade 3/4 adverse events and patients reported less deterioration. In patients with GIST who progressed on or were intolerant to imatinib, the efficacy of Qinlock and sunitinib were comparable, although progression-free survival of Qinlock did not meet the study's primary endpoint of superiority compared to sunitinib. Patients receiving sunitinib were three times more likely to develop Grade 3 hypertension compared to patients receiving ripretinib and patients receiving sunitinib were seven times more likely to develop Grade 3 palmar-plantar erythrodysesthesia compared to patients receiving ripretinib. Patient reported outcome measures also showed a more favorable tolerability profile for patients receiving ripretinib compared to patients receiving sunitinib. Qinlock is approved by the FDA for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

17:07 EST Mustang Bio: FDA issues hold on IND application for MB-207 - Mustang Bio announced that the U.S. FDA has issued a hold, pending Chemistry, Manufacturing and Controls clearance, on the company's Investigational New Drug application. Submitted in December 2021, the IND is to initiate a pivotal Phase 2 multicenter study to assess the safety, tolerability and efficacy of MB-207, Mustang's lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency, also known as bubble boy disease, who have been previously treated with a hematopoietic stem cell transplantation and for whom re-treatment is indicated. The FDA has previously granted MB-207 Orphan Drug and Rare Pediatric Disease Designations. As such, if an MB-207 Biologics License Application is approved by the FDA, then MB-207 would be eligible for a rare pediatric disease voucher.

17:01 EST AnPac Bio receives Nasdaq notification regarding minimum market value - AnPac Bio-Medical Science announced that it has received a written notification from the Nasdaq Stock Market LLC dated January 19, 2022 indicating that the company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(C) requires companies to maintain a minimum MVPHS of $15M, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the company for the 30 consecutive business days from December 3, 2021 to January 18, 2022, the company no longer meets the MVPHS minimum requirement. This notification does not impact the listing and trading of the company's securities at this time. Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), the company has a compliance period of 180 calendar days (or until July 18, 2022) to regain compliance. If at any time during this compliance period the company's MVPHS closes at $15M or more for a minimum of ten consecutive business days, Nasdaq will notify the company that it has achieved compliance with the MVPHS requirement, and the MVPHS matter will be closed. In the event the company does not regain compliance with Rule 5450(b)(2)(C) prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. Alternatively, the company may consider applying to transfer its securities to the Nasdaq Capital Market.

16:32 EST Steel Dynamics CEO expects domestic steel consumption to increase in 2022 - "We believe the market dynamics are in place for domestic steel consumption to further increase in 2022 when compared to 2021," said CEO Millett. "Based on domestic steel demand fundamentals and customer confidence, we believe North American steel consumption will experience steady growth, supported by the construction, automotive, and industrial sectors. Our Structural and Rail Division and steel fabrication operations provide us with more specific insight into the non-residential construction sector, which is the single largest domestic steel consuming sector. Based on our record steel fabrication order backlog extending through most of 2022, combined with the continued strength of order activity and broad customer optimism, we believe construction will remain strong in the coming year. In addition, we believe the more severe supply chain challenges within the North American automotive sector will abate during 2022, supporting stronger production for vehicles that are in high demand and short supply. Steel Dynamics is in a position of strength as we enter 2022. We are ramping up operations at our new state-of-the art electric-arc-furnace flat roll steel mill located in Texas. We had planned to be further along with commissioning the hot side of the steel mill, but supply-chain and COVID challenges delayed the project by several weeks. The team has done a great job with commissioning and operating other aspects of the steel mill, including the rolling mill and two value-added finishing lines, ahead of the melting and casting operations in preparation of full operations commencing before the end of February 2022. Based on our current forecast, we expect shipments to be around 2.0 million tons in 2022. We are also investing approximately $500 million to build four additional value-added flat roll steel coating lines comprised of two paint lines and two galvanizing lines with Galvalume coating capability, a set of which will be located onsite at our new Texas steel mill, providing our new Texas steel mill with the same diversification and higher-margin product capabilities as our two existing flat roll steel divisions. The other two lines will be placed at our Heartland Flat Roll Division located in Terre Haute, Indiana to support growing coated flat roll steel demand in the region and to further increase the diversification and cash generation capacity of our existing Midwest operations. Based on current plans, we believe these four lines will begin operating mid-2023. Our commitment is to the health and safety of our teams, families, communities and to meet the needs of our customers. Our culture and our business model continue to positively differentiate our performance from the rest of the industry. We are competitively positioned and focused to deliver long-term value creation for all of our stakeholders," concluded Millett.

16:31 EST Luxfer announces retirement of CFO Heather Harding, Steve Webster named CFO - Luxfer Holdings announced that Heather Harding, CFO, has elected to retire. Luxfer has appointed Steve Webster as CFO, effective March 1. To ensure an orderly transition, Harding will act as an advisor to the company through December 31, Luxfer said. Webster has served as the company's Corporate Controller for the last six years.

16:30 EST 89bio reports results from expansion cohort of the Phase 1b/2a trial - 89bio announced positive topline results from an open-label expansion cohort of 20 patients in the Phase 1b/2a proof-of-concept study evaluating pegozafermin for the treatment of NASH. "The totality of the pegozafermin data is promising with clinically meaningful changes on histology endpoints, impressive changes on all non-invasive assessments looking at total liver health, as well as significant changes versus baseline in cardiovascular markers and glycemic control," said Rohit Loomba MD, MHSc, Director of the NAFLD Research Center, University of California San Diego and primary investigator of the study. "NASH is a complex disease and addressing overall liver health together with treating the underlying drivers of the disease is important in considering therapeutic options for our patients."

16:26 EST Hydrofarm, AXEON Water Technologies enter strategic partnership - Hydrofarm Holdings announced it has entered into an agreement with California-based AXEON Water Technologies , a leading manufacturer of water purification solutions, to distribute new lines of reverse osmosis water filtration systems and solutions for the horticultural market. The partnership between AXEON and Hydrofarm will allow for many of the nation's top retailers and professionals to gain access to high-quality, technologically advanced purification systems and membrane filtration solutions. "AXEON will be introducing several new reverse osmosis and filtration system designs that bring cutting-edge technologies, aesthetics and performance to growers around the world," said Bill Toler, Chairman and Chief Executive Officer of Hydrofarm. "We're excited to partner with the AXEON team and bring these new products to market." For over 30 years, AXEON has offered the industry's most reliable water filtration systems that are backed by the highest level of customer and technical support, in addition to an ironclad customer satisfaction and warranty policy.

16:20 EST Opiant adds $2.2M funding under BARDA contract - Opiant Pharmaceuticals announced a modification to its contract with the Biomedical Advanced Research and Development Authority for an additional commitment of up to $2.2M to support OPNT003, nasal nalmefene, for opioid overdose. The increase in funding is primarily directed toward the costs of Opiant's clinical studies to support its submission of OPNT003 to the Food and Drug Administration. Opiant is currently completing a non-inferiority pharmacodynamic study comparing nasal nalmefene with nasal naloxone in reversing respiratory depression produced by remifentanil, a synthetic opioid. In a confirmatory pharmacokinetic study, conducted last year, OPNT003 exhibited fast absorption and high plasma concentrations that surpassed intramuscular nalmefene, as well as a comparable long duration. These are attributes that support OPNT003 as a potential major advance in opioid overdose reversal. OPNT003 is being developed using a 505(b)(2) pathway, with PK and PD studies supporting NDA submission. In November 2021, the FDA granted OPNT003 Fast Track Designation. "A national crisis of opioid overdose requires innovation to save lives, and we believe OPNT003, nasal nalmefene, has the potential to offer an important new overdose treatment in the community," said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. "BARDA has been an outstanding partner for OPNT003, and we are excited to advance closer to New Drug Application submission this year with their support." Opioid overdose is a significant public health crisis that has been exacerbated by the increased availability and abuse of synthetic opioids, such as fentanyl. In a 12-month period that ended in June 2021, over 76,000 people in the U.S. died from an opioid overdose.

16:19 EST Equity Lifestyle raises annual dividend for FY22 by 13% to $1.64

16:17 EST Argan boosts share repurchase program to $50M from $25M - Argan announced that its board of directors approved an increase in the company's existing share repurchase program, from $25M to $50M, to acquire shares of the company's Common Stock. The company has repurchased shares at a cost of approximately $18M under the authorization to-date. "Delivering value to our customers and stockholders is our top priority. We are committed to a disciplined capital allocation strategy that balances returning capital to our stockholders and investing in our business and people," said Rainer Bosselmann, Argan's Chairman and Chief Executive Officer. "Over the past two months, we have repurchased $18 million of shares, and over the past two years, we have distributed dividends of approximately $63 million, while at the same time building our cash and net liquidity. As a result, with the meaningful free cash flow from our business, we expect to maintain share repurchasing as an opportunistic part of our capital allocation strategy."

16:16 EST Meta Platforms provides update on new segment reporting - The company stated: "Following Meta Platforms October 2021 announcement that we would implement a new financial reporting structure, we are sharing additional information about the reporting format of our segmented financials. Beginning with the fourth quarter 2021 earnings results on February 2, 2022, Meta will report revenue and income (loss) from operations for the following two segments: Family of Apps includes Facebook, Instagram, Messenger, WhatsApp and other services. We will continue to report total advertising revenue and advertising revenue by user geography using our legacy methodology. We will also report other revenue, which consists of net fees we receive from developers using our payments infrastructure and revenue from various other sources, within the Family of Apps segment. Reality Labs includes augmented and virtual reality related consumer hardware, software and content. In addition to reporting segment financials for the fourth quarter of 2021, we will provide historical segment information for all quarters of 2021, the fourth quarter of 2020, and full years 2019, 2020 and 2021."

16:13 EST Flexsteel Industries board approves new $30M buyback program - On January 20, 2022, the Flexsteel board approved a new repurchase program authorizing the company to purchase up to an aggregate of $30M of the company's common stock. There is no guarantee as to the exact number or value of shares that will be repurchased by the company, and the company may discontinue repurchases at any time that management determines additional repurchases are not warranted. The timing and amount of share repurchases under the $30M share repurchase program will depend on several factors, including the company's stock valuation, ongoing capital planning considerations and cash priorities, general market conditions and applicable legal requirements.

16:12 EST IBM jumps 6% to $137.00 after Q4 results beat estimates

16:06 EST ICF International names Barry Broadus as CFO, effective February 28 - ICF announced that it plans to name Barry Broadus CFO, effective February 28. Broadus will replace Bettina Garcia Welsh, who will be leaving ICF to pursue new opportunities. Welsh has agreed to stay on at ICF as an advisor through early April to ensure a seamless transition. Most recently, Broadus was the CFO of Dovel Technologies a provider of technology solutions to federal government agencies with a focus in the health, human services and public safety markets that was acquired in October 2021. Previously Broadus served as CFO of SRI International, Constellis, and Alion Science and Technology.

16:06 EST CSX names Sean Pelkey CFO - CSX announced the appointment of Sean R. Pelkey as executive vice president and chief financial officer effective immediately. James M. Foote, president and chief executive officer said: "Sean has played an important role as a member of the CSX leadership team throughout our transformation, which has delivered superior value to our many stakeholders. Sean's strong financial acumen, deep railroad industry knowledge, and broad experience at CSX will be invaluable as we strive to deliver profitable and sustainable growth." Mr. Pelkey, who most recently served as vice president and acting chief financial officer, joined the company in 2005. From 2017 to June 2021, he was vice president of Finance and Treasury. He has over 16 years of experience in finance and capital management, and previously served as assistant vice president, capital markets and investor relations. He holds a master's degree in business administration from the University of Florida and a bachelor's degree in sociology from Boston University.

16:03 EST Allscripts raises FY21 adjusted EBITDA view to $295M-$300M from $275M-$285M

15:34 EST Unity acquires Ziva Dynamics, terms not disclosed - Unity said it has acquired Ziva Dynamics, a player in sophisticated simulation and deformation, machine learning, and real-time character creation. "We, as humans, are uniquely attuned to react to human movement," Unity said in a blog post. "We have an entire section of our brains dedicated to rapidly processing faces and expressions. Creating digital humans that meet the quality and natural dynamics needed to truly satisfy our minds can be a complicated and painful effort, requiring both expert knowledge and extreme perseverance. Ziva Dynamics is solving that problem. The Ziva team has deep expertise and understanding of complex anatomical simulation and real-time artistry tools. Their incredible technology is paving the way for lifelike real-time characters and scalable, accessible workflows." Reference Link

14:17 EST Apple extends deadline for event in-app purchases, account deletion - Apple said over the weekend that it has changed the following requirement deadlines to June 30, 2022: online group event in-app purchases, and; account deletion within apps. Given the recent resurgence of COVID and its continued impact on in-person services, the company extended the most recent deadline to June 30, 2022. In addition, Apple noted that the requirement for app deletion was set to apply to all app submissions by January 31, 2022. Due to the complexity of implementing this requirement, the company extended the deadline to June 30, 2022 to give users more time. Reference Link

13:51 EST IO Biotech Inc trading halted, volatility trading pause

13:45 EST Polymet Mining trading resumes

13:31 EST AIkido Pharma announces $3M share repurchase program - AIkido Pharma announced that its board of directors has authorized a share repurchase program to repurchase up to $3M of the company's outstanding common stock. The share repurchase authorization is effective immediately. "The Board's decision to establish this share repurchase program reflects the company's commitment to creating shareholder value, our strong balance sheet and the expectations we have for 2022. We will continue our efforts to create shareholder value by continuing to prioritize capital allocation that supports our growth strategies. Further, we anticipate several monetization events this year, from several of our recent investments, which we believe will further augment shareholder value," said Anthony Hayes, CEO of AIkido.

12:47 EST Chanos says 'doesn't mind being long market at 18-times earnings' - Jim Chanos, founder of Kynikos Associates, is speaking on CNBC.

12:36 EST Chanos says Kynikos 'slightly net long' market in 2022 - Jim Chanos, founder of Kynikos Associates, is speaking on CNBC.

12:23 EST Pure Storage trading resumes

12:01 EST WeWork falls -19.5% - WeWork is down -19.5%, or -$1.73 to $7.12.

12:00 EST AMTD International falls -36.3% - AMTD International is down -36.3%, or -$1.85 to $3.25.

12:00 EST Kohl's rises 34.8% - Kohl's is up 34.8%, or $16.30 to $63.14.

11:59 EST Pure Storage trading halted, news pending

11:31 EST AMTD International Inc trading resumes

11:16 EST Intergrated Media Technology Ltd trading halted, volatility trading pause

11:12 EST Arrow Electronics, Appletec sign agreement for supply of compact camera modules - Arrow Electronics has signed an agreement with Israeli company Appletec under which Appletec will produce a range of compact camera modules exclusively for Arrow. The CCMs are intended for developers who want to add an embedded vision capability to products used in sectors including industrial, medical, security and automotive. A customisation service will be available to support a variety of interconnect solutions. System developers can write their own software drivers for the CCMs or make use of the driver produced by eInfochips, an Arrow company, which is due to be released at the end of Q1 2022.

11:03 EST Arrow Electronics, Appletec sign agreement for supply of compact camera modules - Arrow Electronics has signed an agreement with Israeli company Appletec under which Appletec will produce a range of compact camera modules exclusively for Arrow. The CCMs are intended for developers who want to add an embedded vision capability to products used in sectors including industrial, medical, security and automotive. A customisation service will be available to support a variety of interconnect solutions. System developers can write their own software drivers for the CCMs or make use of the driver produced by eInfochips, an Arrow company, which is due to be released at the end of Q1 2022.

10:58 EST Fortuna Silver Mines reports no effect from political events in Burkina Faso - Fortuna Silver Mines reports that its Yaramoko gold Mine located in Burkina Faso, its workforce and associated supply chains have not been affected by the current political situation and its operations continue as normal. The Company continues to monitor the situation and will provide updates as and when required

10:46 EST FDA approves GSK's Nucala 40 mg prefilled syringe for kids with type of asthma - GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved a 40 mg prefilled syringe of Nucala for appropriate children aged 6 to 11 years old who have severe eosinophilic asthma, or SEA. "Nucala can now be given by a child's health care provider or administered at home by a caregiver once trained by a health care professional. Nucala is an add-on, prescription maintenance treatment for patients 6 years and older with severe eosinophilic asthma. Previously, children aged 6 to 11 years old received a dose of 40 mg Nucala using a solution that was mixed and administered in a physician's office. Now, a child's healthcare provider will determine if at-home administration is appropriate, and if so, will provide instruction to a patient's caregiver on how to properly administer and monitor for any allergic reactions. Nucala will be administered every four weeks whether at home or in the physician's office," the company stated.

10:36 EST Natuzzi trading resumes

10:28 EST TKLF Stock trading halted, volatility trading pause

10:10 EST Genentech announces publication of two papers on faricimab study results - Genentech announced The Lancet has published two papers highlighting one-year results from four pivotal Phase III studies of faricimab, an investigational bispecific antibody, in wet, or neovascular, age-related macular degeneration and diabetic macular edema. All four studies - which enrolled more than 3,000 people in total - met their primary endpoints, showing that patients treated with faricimab up to every four months achieved non-inferior vision gains compared to aflibercept, given every two months. Notably, about half of eligible faricimab patients were able to go four months between treatments in the first year, and approximately three-quarters could go three months or longer in the TENAYA and LUCERNE wet AMD studies and the YOSEMITE and RHINE DME studies. The current standard of care for these potentially blinding conditions requires eye injections as often as once a month. If approved, faricimab would be the first bispecific antibody for the eye, targeting and inhibiting two distinct pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 and vascular endothelial growth factor-A. Inhibition of both pathways has been shown to have complementary benefits, stabilizing vessels and thereby reducing vessel leakage and inflammation more than inhibition of the VEGF-A pathway alone. In the TENAYA and LUCERNE studies in wet AMD, the average vision gains from baseline at one year in the faricimab arms were +5.8 and +6.6 letters, respectively, compared to +5.1 and +6.6 letters in the aflibercept arms. The studies also measured the proportion of people in the faricimab arm that were treated on dosing schedules of every three or four months during the first year. Importantly, 46% of patients in TENAYA and 45% in LUCERNE were able to be treated every four months in the first year. An additional 34% of patients in TENAYA and 33% in LUCERNE were able to be treated every three months. Combined, nearly 80% of faricimab-treated patients were able to go three months or longer between treatments during the first year. Consistent with vision outcomes, faricimab treatment resulted in a meaningful and comparable reduction in central subfield thickness and comparable decreases in choroidal neovascularization lesion size and area. Faricimab was generally well-tolerated in both studies, with a favorable benefit-risk profile. Ocular adverse events were comparable across treatment arms and consistent with those expected with intravitreal anti-VEGF injections in patients with wet AMD. In the YOSEMITE and RHINE studies in DME, the average vision gains from baseline at one year were +11.6 and +10.8 eye chart letters in the faricimab treat-and-extend arms, +10.7 and +11.8 letters in the two-month arms, and +10.9 and +10.3 letters in the aflibercept arms, respectively. A secondary endpoint in both studies measured the proportion of people in the faricimab treat-and-extend arms that achieved dosing schedules of every three or four months at the end of the first year. Importantly, 53% of faricimab treat-and-extend patients in YOSEMITE and 51% in RHINE achieved four-month dosing at one year. An additional 21% of faricimab treat-and-extend patients in YOSEMITE and 20% in RHINE achieved three-month dosing. Combined, more than 70% of faricimab treat-and-extend patients were able to go three months or longer between treatments at the end of the first year. Reductions in CST and resolution of intraretinal fluid through the first year consistently favored faricimab over aflibercept. Faricimab was generally well-tolerated in both studies, with a favorable benefit-risk profile. Ocular AEs were comparable across treatment arms and consistent with those expected with intravitreal anti-VEGF injections in patients with DME. Faricimab is currently under review by the U.S. Food and Drug Administration for the treatment of wet AMD and DME. The European Medicines Agency is also currently evaluating the faricimab Marketing Authorization Application for the treatment of wet AMD and DME. Additionally, the COMINO and BALATON trials are underway, evaluating the efficacy and safety of faricimab in people with macular edema following retinal vein occlusion. Two-year results for faricimab in DME will be presented at the Angiogenesis, Exudation, and Degeneration 2022 meeting, on Saturday, February 12.

10:03 EST S&T Bank promotes Steve Drahnak to chief commercial banking officer - S&T BanK is proud to announce the promotions of three executives into critical roles to support the company's continued growth and success. Steve Drahnak has been promoted to chief commercial banking officer and will continue to report to David Antolik, president. He currently serves as the bank's market president for western Pennsylvania. Steve will continue in that role and will assume responsibility for all aspects of commercial banking, including oversight of commercial & industrial, commercial real estate , business credit, and treasury management. Heidi Williams has been promoted to senior vice president, community market executive and CRE team manager for western Pennsylvania. In her new role, Heidi will be responsible for driving collaboration between all business lines and serving as the primary authority for complex consumer and commercial banking functions. She leads the community market's CRE banking team including commercial bankers, portfolio managers, and loan documentation officers. Jonathan Kowalski has been promoted to senior vice president, metro market executive and C&I team manager for western Pennsylvania. In his new role, Jon will be responsible for driving collaboration between all business lines and serving as the primary authority for complex consumer and commercial banking functions. He leads the metro market's C&I banking team including commercial bankers, portfolio managers, and loan documentation officers.

10:01 EST Trio-Tech resumes operations at Tianjin City facility - Trio-Tech International announced that it has resumed full operations at the Company's Tianjin, China, facility. S.W. Yong, Trio-Tech's CEO, said, "On Thursday, January 20, the Tianjin City Government removed the lockdown measures and we commenced resuming operations at our facility. By Friday, January 21, 2022, our Tianjin operations achieved 100% operating capacity. We are actively working on our production output to catch up with backlog. Trio-Tech Tianjin was in full cooperation with the lockdown mandate imposed by the Tianjin City Government and we are resuming operations cautiously with stringent health and safety measures as required by the local government mandate. Throughout the lockdown, our primary concern has been the safety of our employees, customers, suppliers and the Tianjin community as a whole. We expect to continue working closely with local authorities to achieve safe, long-term, COVID-19 compliant operations consistent with the needs of the Tianjin City authorities."

10:00 EST Hayward falls -11.3% - Hayward is down -11.3%, or -$2.38 to $18.75.

10:00 EST Adtalem Global Education rises 11.6% - Adtalem Global Education is up 11.6%, or $3.24 to $31.14.

10:00 EST Exterran rises 45.3% - Exterran is up 45.3%, or $1.36 to $4.36.

09:51 EST Netherlands orders Apple to pay first penalty payment of EUR 5M - Apple has failed to satisfy the requirements set by the Netherlands Authority for Consumers and Markets regarding payment systems for dating-app providers, the agency said in a statement. ACM has come to this conclusion following an investigation into Apple's statements of January 15. This means that Apple now has to pay ACM the first penalty payment of 5M euros. "Apple must adjust its conditions for access to the Dutch App Store for dating-app providers. In the App Store, dating-app providers must also be able to use payment systems other than Apple's payment system," the agency said. Apple "has failed to satisfy the requirements on several points, "it added. ACM has informed Apple that its statements do not satisfy the requirements laid down in the order subject to periodic penalty payments. "Apple is still obligated to act in accordance with said order. If it fails to do so, Apple will have to pay each week a penalty payment of 5 million euros up to a maximum of 50 million euros," it noted. Reference Link

09:47 EST GreenTree Hospitality falls -10.6% - GreenTree Hospitality is down -10.6%, or -71c to $6.01.

09:47 EST Sunlands Online falls -11.7% - Sunlands Online is down -11.7%, or -72c to $5.41.

09:47 EST Kohl's rises 31.1% - Kohl's is up 31.1%, or $14.55 to $61.39.

09:43 EST AMTD International Inc trading resumes

09:32 EST Harbor Custom Development accepts bitcoin, cryptocurrencies for real estate - Harbor Custom Development announced it will accept Bitcoin and 12 other digital currencies as payment for its listed land, developed lots, residential homes, condominiums, and apartments in the Company's operating markets in Washington, California, Texas, and Florida. In addition to Bitcoin, the Company also accepts: Ethereum, USD Coin, XRP, Dogecoin, SHIBA INU, Binance USD, Wrapped Bitcoin, Litecoin, Dai, Bitcoin Cash, Pax Dollar and Gemini Dollar. Harbor uses a third-party company that converts cryptocurrencies to U.S. dollars and those funds are sent to escrow to close the transaction. All real estate transactions are settled in U.S. dollars.

09:22 EST Biotricity receives FDA 510-k clearance for Biotres cardiac monitoring device - Biotricity reported it has received 510k clearance from the U.S. Food and Drug Administration for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO commented, "We are extremely proud of this accomplishment and its potential to reshape the future of cardiac prevention and monitoring with this novel platform. With Biotres receiving 510 clearance, we now have another option for providing a secondary product for doctors and hospitals to meet their patients' cardiac monitoring needs. Coupled with the recent successful non-dilutive financing, we believe we are well capitalized to execute the expansion of our commercialization efforts." "Biotres, is a holter for low-risk patients and is designed for comfort for long-term wear," he added. "Cardiac disease remains a chronic issue, requiring persistent intervention, monitoring and management and we believe Biotres may provide a critical tool for improving patient lives and reducing costs." Designed to address the current limitations of existing holter monitors technologies, Biotres offers the following feature set: 3 Channel Recording - A wearable holter patch device that can provide continuous 3 channel recording of ECG data. All other known holter patch devices are 1 channel or 2 channels.

09:20 EST Halliburton starting 2022 a lot higher despite typical Q1 seasonality

09:18 EST Kreatorhood selects Nuvei to power payments for digital content creators - Nuvei Corporation announced it has been selected by Kreatorhood to power payments for digital content creators and sellers around the world. Kreatorhood is an NFT marketplace focused on art, music, performance and sports that helps creators turn their digital content into limited edition NFTs on the blockchain. Kreatorhood's mission is to accelerate the mainstream adoption of NFTs. Through its proprietary technology, Kreatorhood removes the barriers to entry of buying and selling NFTs. The partnership with Nuvei enables Kreatorhood's client network to enjoy a seamless payment experience across the blockchain and all payment methods, no matter where they are located.

09:17 EST NCS Multistage wins patent infringement case against Nine Energy Service - NCS Multistage Holdings (NCSM) announced that a jury in the U.S. District Court for the Western District of Texas, Waco Division has found that Nine Energy Service's (NINE) BreakThru casing flotation device infringes on an NCS patent, U.S. Patent No. 10,465,445. The jury awarded NCS approximately $486,000 in damages for infringement of the patent from the patent issue date, November 5, 2019, through the end of trial. "We are very pleased with the unanimous jury verdict from last Friday," said Robert Nipper, NCS's CEO. "Our Airlock casing buoyancy system pioneered a new way to float casing in the wellbore and the jury verdict requires Nine to recognize the value of our patent and innovation. NCS's portfolio of over 100 issued patents is the result of more than a decade of hard work by NCS employees. The patent system, founded in the US constitution, provides a framework for us to protect the inventions we develop for our customers, allowing them to save time and money, and to improve the environmental footprint of their operations. The ruling further validates that our legal system will support its innovators and protect them from those that seek to gain by infringing on the intellectual property rights of others. This reinforces our continued drive to deliver new technologies that bring enhanced efficiency and value to our customers."

09:08 EST Motorsport Games' Le Mans Virtual Series followed by over 81M fans - The five-round 2021-22 Le Mans Virtual Series, which was brought to a conclusion last weekend with the 24 Hours of Le Mans Virtual, registered cumulated TV and digital audience figures of more than 81 million throughout its 5-month season. The grand finale to the Le Mans Virtual Series held on January 15 and 16, 2022 brought together 50 cars with 200 drivers hailing from 39 different countries. Racers competed on 116 simulators worldwide located in 28 countries on an extremely accurate virtual rendition of the iconic Circuit des 24 Heures in Le Mans, France. Heading a grid of famous racing names and leading the charge in early stages was Formula One World Champion Max Verstappen, competing alongside INDYCAR Champion Alex Palou and motorsport legend Juan Pablo Montoya, among others. After battles up and down the field between the world's best professional and sim racing drivers representing elite esports teams, the event was won by Realteam Hydrogen Redline, with BMW Team Redline taking victory in the GTE category.

09:06 EST Seanergy Marine sees Q4 average TCE rate exceeding $36,000 per ship per day - Seanergy Maritime Holdings updated its time charter equivalent guidance upwards for the fourth quarter of 2021, provided preliminary TCE guidance for the first quarter of 2022, as well as EBITDA projections for FY 2022. In the fourth quarter of 2021, the Company is expected to exceed an average TCE rate of approximately $36,000 per ship per day, outperforming our previously announced guidance of $35,200 per ship per day. The company said, "As of the date of this press release, our estimated TCE rate for the first quarter of 2022 is expected to be approximately $19,000. This estimate assumes that the remaining unfixed operating days of our index-linked vessels for this period will be equal to the average Forward Freight Agreement rate of $13,500 per day. Our TCE guidance for the first quarter includes certain conversions of index-linked charters to fixed, which were concluded in the third and fourth quarter of 2021, as part of our freight hedging strategy." Stamatis Tsantanis, the Company's Chairman & CEO, stated: "As a result of our pro-active hedging strategy in 2H21, we estimate that we will overperform the current spot market rate by approximately 50% in the first quarter. Moreover, our robust EBITDA generating capacity in multiple freight environments attests to our firm belief that our shares are currently significantly undervalued. Despite the seasonal market weakness, we expect that supply and demand fundamentals will result in a strong recovery of Capesize rates within the following months. Our solid balance sheet, modern fleet and strong relationships with world leading charterers in combination with our substantial operating leverage place Seanergy in an optimal position to generate strong revenues and profitability in an improving charter rate environment."

09:05 EST FuboTV secures rights to stream select UEFA matches - FuboTV announced it has secured exclusive U.S. rights through a six-year sublicense with FOX Sports to stream select matches from Union of European Football Associations, or UEFA. The deal kicks off with the UEFA Nations League in June. Terms of the deal were not disclosed.

09:05 EST Halliburton sees improved service price in North American, international market

09:04 EST OpenText announces changes to executive leadership team - OpenText announced certain strategic appointments and changes to its Executive Leadership Team. Sandy Ono has been appointed as Chief Marketing Officer. Ono joins OpenText from Hewlett Packard Enterprise, where she most recently served as VP, Growth Marketing. Prior to HPE, Ono held a variety of roles in strategy consulting and business development including time with Deloitte and the Walt Disney Company. Michael Acedo has been promoted to Chief Legal Officer & Corporate Secretary. Acedo joined OpenText in 2014 from global law firm Skadden, Arps, Slate, Meagher & Flom. At OpenText, he most recently served as the Vice President, General Counsel - Corp. & Corporate Secretary. Doug Parker has been promoted to Executive VP, Corporate Development. Parker served as President & CEO of Quarterhill, focused on the acquisition, management and growth of companies in dedicated technology areas. Gordon Davies, Executive VP, Chief Legal Officer and Corporate Development has decided to retire effective September. Until such time, Davies will act as Special Advisor to the CEO. The appointments and changes are effective immediately.

09:02 EST Sorrento Therapeutics receives purchase order for 10M covistix tests - Sorrento Therapeutics and Sorrento Mexico announced that COFEPRIS has given EUA approval to Sorrento Mexico to import, market and distribute COVISTIX tests directly in Mexico. COVISTIX is a sensitive platinum colloid-based lateral-flow rapid antigen test for the detection of SARS-CoV-2 infection. "The situation in Mexico is quite serious, and Sorrento and Sorrento Mexico are doing everything we can to increase testing capacity for the people of Mexico," said Dr. Henry Ji, President and CEO of Sorrento. Following receipt of the EUA approval and on January 20, 2022, Sorrento Mexico has placed directly to Sorrento, a purchase order for 10M COVISTIX tests to be delivered in February. Sorrento Mexico anticipates the current demand for COVISTIX testing in Mexico is far exceeding the current order.

08:45 EST Solarwindow appoints John Rhee as chairman, CEO - SolarWindow Technologies announced that John Rhee has been elected to serve as its Chairman of the Board of Directors and CEO, in addition to his current role as President of SolarWindow. Rhee also serves as Managing Director of Light Quantum Energy Holdings, a company owned by Rhee and his immediate family, which last month acquired nearly 72% of SolarWindow shares on a fully diluted basis. Rhee's first action as SolarWindow CEO is the appointment of former senior executives at LG Fuel Cells, LG Display, and LG Electronics, to lead SolarWindow into manufacturing. Promoted to SolarWindow Chief Technology Officer, Dr. In Jae Chung is a C-level executive with 30 years of multinational experience in intellectual property, new product development and manufacturing, sales and marketing, and commercial partnerships. Prior to SolarWindow, Dr. Chung was CEO at LG Fuel Cell Systems, and CTO at LG Display, a business unit reporting over $20 billion in annual sales and supported by more than 15,000 patents. Chulwoo Kim has been appointed to Global Director, Technology and Product Innovation; a position previously held by Dr. Chung. Mr. Kim formerly served as Vice President at LG Electronics and Vice President LG Display, where during his tenure he oversaw over 20,000 employees and $10 billion in production volume for complex manufacturing of select consumer technology products. Making way for Rhee, the Company's former Chairman and CEO Jatinder Bhogal exits SolarWindow to continue his work in disruptive technologies and new venture development. Bhogal continues to support SolarWindow as an advisor.

08:42 EST Paya Holdings announces partnership with Transcard - Paya announced its partnership with Transcard. Through the integration of Transcard's technology and banking infrastructure, Paya will substantially expand its B2B commerce solution suite, adding a fully-integrated accounts payable module and supplier network. This new partnership will enable Paya's customers to seamlessly send payments, coupled with rich data, to their suppliers via ACH and virtual card, reducing the back-office burden caused by paper checks. Further, by offering comprehensive AP automation and payments combined with its leading accounts receivable and cash application capabilities, Paya becomes a "one-stop shop" for payments, workflow, and working capital management-capabilities that can be seamlessly integrated into CRM and accounting software used by sophisticated B2B merchants across Paya's high-growth verticals. The integrated AR and AP solutions will be offered through a single API and a single portal, enabling businesses to interact with their customers and vendors in a simplified and efficient manner, while providing scale and operational efficiency to the back-office.

08:38 EST HUMBL announces addition of BLOCKS to HUMBL Pay mobile wallet - HUMBL announced the addition of BLOCKS to its HUMBL Pay mobile wallet. The HUMBL Pay mobile wallet features the ability to buy crypto and send gasless, peer-to-peer transactions on over 20+ digital assets, such as Bitcoin, Ethereum, BLOCKS and USDC Stablecoins. As of today, HUMBL Pay customers can now buy BLOCKS using ACH, credit card and debit card directly inside the HUMBL Pay mobile wallet; as well as send BLOCKS via gasless, peer-to-peer transactions to other HUMBL Pay users inside the HUMBL Pay mobile wallet. HUMBL is also working on the ability for customers to receive BLOCKS from external wallets, as well as adding BLOCKS swaps with digital assets such as Bitcoin, Ethereum and USDC inside the HUMBL Pay wallet.

08:38 EST Vonage to power VIRA vaccine chatbot for WhatsApp - Vonage is partnering with WhatsApp to power the expansion of the COVID-19 vaccine VIRA chatbot to WhatsApp users. VIRA, short for Vaccine Information Resource Assistant, provides critical, dependable COVID-19 vaccine-related information on-the-go, to anyone around the globe. The VIRA chatbot was developed by the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health with experts from the Bloomberg School's Department of International Health and Johns Hopkins Whiting School of Engineering. VIRA will be a part of WhatsApp's global COVID-19 Program. The Vonage Messages API embeds the VIRA chatbot into WhatsApp, sending notifications, messages, and essential, targeted information users need, in real-time.

08:37 EST B.O.S. Better Online's Robotic Division receives $630,000 order - BOS Better Online Solutions announced that its Intelligent Robotic Division has received a $630,000 order for an industrial robotics and automation line, from an Israeli customer.

08:36 EST Nano Dimension establishes AME NanoLab Facility with TTM Technologies - Nano Dimension (NNDM) announced a collaboration with TTM Technologies (TTMI) to open its first AME NanoLab at TTM's Advanced Manufacturing Center in Stafford Springs, CT. The AME NanoLab Network will enable customers and researchers to actively experience the complete AME workflow in two steps, from design to final prototype. This network of labs will allow clients to take advantage of the latest DragonFly IV 3D-Printer and FLIGHT software from Nano Dimension. Experts will be on hand to work one-on-one with defense, aviation, aerospace, medical, advanced industrial, and research users to support them in accelerating the development cycles for novel electronic products. By launching the first site, named AME NanoLab@TTM, Nano Dimension and TTM intend to drive growth and new capabilities in the AME market. The alliance will draw upon TTM's expertise in the printed circuit board industry and deliver innovations and solutions using advanced composition and manufacturing techniques. TTM already owns and operates three Nano Dimension DragonFly systems at its Advanced Manufacturing Center. The AME NanoLab @ TTM, and the launch of additional AME NanoLab Network sites in the future, will spearhead the ongoing development of new specifications related to IPC, MILSPEC, and Automotive and will work toward creating new AME standards within the United States. Customers will also receive critical training and consulting on their applications and use cases.

08:35 EST F.N.B. completes merger with Howard Bancorp - F.N.B. Corporation (FNB) announced that it successfully completed its merger with Baltimore, Maryland-based Howard Bancorp (HBMD) on January 22. The customer and branch branding conversion is scheduled to be finalized on February 7. Shares of Howard common stock will no longer be traded on NASDAQ.

08:34 EST Guardion Health Sciences launches online store for Viactiv - Guardion Health Sciences announced the launch of its new branded Shopify store for its Viactiv line of products, https://viactiv.com. The new e-commerce venue offers Viactiv customers an omni-channel experience, allowing them to shop via retail outlets or online either through those same retail websites or directly through the Company itself in its new branded website. The store features all of Viactiv's current product line, including newly launched Calcium+Immune, which features high potency levels of Vitamin D3 and zinc to support and boost the immune system. The site also features legacy products, Calcium+Bone Strengthening and Calcium+Bone Strengthening. In addition, the new e-store features a "Learn" section, which offers nutrition tips, ingredient information, and a deeper dive into the custom-designed clinical benefits supporting the Viactiv line.

08:34 EST Kohl's confirms receipt of letters expressing interest in acquiring company - Kohl's confirmed that it has received letters expressing interest in acquiring the company. "The Kohl's board of directors will determine the course of action that it believes is in the best interests of the company and its shareholders. Shareholders are not required to take any action at this time. Kohl's does not intend to further comment publicly on these matters unless it determines it is in the best interests of shareholders to do so," the company stated in a press release.

08:33 EST Sharps Compliance partners with PharMerica to bring MedSafe to LTC facilities - Sharps Compliance announces its partnership with PharMerica Corporation to make the Sharps MedSafe available to the long-term care, LTC, facilities in PharMerica's network. PharMerica currently works with more than 2,500 facilities across the U.S. Commenting on the partnership, David Tusa, President and Chief Executive Officer of Sharps Compliance, stated, "We are proud and excited to work with PharMerica to provide our industry-leading MedSafe solution to the communities they serve. We believe this partnership presents a tremendous opportunity to provide MedSafe's capabilities to a broader population of LTC locations to help them efficiently address the cost and complexities of DEA and EPA compliant medication management, while also reducing facility operating expenses."

08:32 EST Marriott Vacations reports Q4 contract sales of $406M - Marriott Vacations reported Q4 contract sales. In its Vacation Ownership business, the company continued to experience "strong" occupancies at most of its resorts during Q4 and volume per guest remained well above pre-pandemic levels. As a result, the company delivered contract sales of $406M for Q4.

08:31 EST Kohl's confirms letters of interest - Kohl's confirmed that it has received letters expressing interest in acquiring the company. The Kohl's board of directors will determine the course of action that it believes is in the best interests of the company and its shareholders. Shareholders are not required to take any action at this time. Kohl's does not intend to further comment publicly on these matters unless it determines it is in the best interests of shareholders to do so.

08:27 EST Eagle Bancorp announces private placement of subordinated notes due 2032 - Eagle Bancorp Montana announced that it has issued and sold $40M in aggregate principal amount of its 3.50% fixed-to-floating rate subordinated notes to certain institutional accredited investors and qualified institutional buyers through a private placement offering. The subordinated notes were issued on January 21, 2022 and will mature on February 1, 2032. The subordinated notes will bear interest at an annual fixed rate of 3.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year from August 1, 2022 to, but excluding, February 1, 2027. From and including February 1, 2027 to, but excluding, February 1, 2032 or the earlier redemption date, interest will accrue at a floating rate per annum equal to a benchmark rate, which is expected to be three-month term SOFR, plus a spread of 218.0 basis points, payable quarterly in arrears on February 1, May 1, August 1 and November 1 of each year. The Company estimates that the net cash proceeds from the sale of the subordinated notes will be approximately $39.1M, and the subordinated notes are expected to qualify as Tier 2 capital for regulatory purposes. The Company intends to use the net proceeds from the offering for general corporate purposes, including but not limited to providing capital to support its acquisition of First Community Bancorp and the redemption of the Company's outstanding $10M of 5.75% senior notes due February 15, 2022. In connection with the sale and issuance of the Notes, the Company entered into a Registration Rights Agreement with the purchasers of the Notes pursuant to which the Company has agreed to take certain actions to provide for the exchange of the Notes for subordinated notes that are registered under the Securities Act of 1933, as amended, and have substantially the same terms as the Notes. Under certain circumstances, if the Company fails to meet its obligations under the Registration Rights Agreement, it would be required to pay additional interest to the holders of the Notes

08:25 EST Asure Software, Certegy partner for technology integration - Asure Software announced a new partnership with Certegy, a provider of payment and risk management technology for retailers and financial institutions. The company said, "Connecting Asure's 80,000+ Payroll and HR business customers with Certegy's Positive Pay program enables these businesses to now offer their unbanked employees more options when cashing their paper checks. In turn, this increases our business customers' ability to retain and recruit employees. Certegy's Positive Pay program enables quick approval for checks on record while preventing fraud. The information provided by check issuers is used to validate checks upon presentment at 100,000+ retailers throughout the US. This validation process greatly reduces risk for check cashing retailers, which allows these retailers to assess a lower check-cashing fee to customers of enrolled companies."

08:20 EST Franklin Electric raises quarterly dividend 11% to 19.5c per share - Franklin Electric announced that its Board of Directors declared a quarterly cash dividend of 19.5c per share payable February 17, 2022, to shareholders of record on February 3, 2022. This represents an 11 percent increase from the prior quarterly dividend.

08:18 EST Endra revives IRB approval from Shanghai General Hospital for TAEUS study - Endra Life Sciences announced it has received Institutional Review Board approval from China's Shanghai General Hospital, for the first clinical study of Endra's Thermo Acoustic Enhanced UltraSound device to assess Non-Alcoholic Fatty Liver Disease in that market. The study is expected to begin in 2022.

08:17 EST Avita Medical's RECELL system to be presented at burn, wound care symposium - AVITA Medical announced that six abstracts highlighting the clinical benefits of the RECELL Autologous Cell Harvesting Device have been accepted at the 44th Annual John A. Boswick Burn & Wound Care Symposium. The international conference will be held in Maui, Hawaii, January 22-27, and covers the latest advancements in burn care, wound healing, and infection control. "The physician-initiated research being presented at this year's Boswick Symposium underscores how the RECELL System is advancing treatment of burn wounds, both as a monotherapy and in combination with complementary technologies," said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. "With completion of enrollment in both our vitiligo and soft tissue reconstruction pivotal clinical trials, we look forward to progressing our pipeline and simultaneously beginning to realize the immense potential of this innovative technology platform benefitting a broad array of patients with skin defects or wounds."

08:16 EST Lionheart Acquisition urges stockholders to vote for extension amendment - Lionheart Acquisition Corporation II encourages its stockholders to vote in favor of the proposal to amend its charter to extend the date by which the Company has to complete a business combination from February 18, 2022 to August 18, 2022. A special meeting of the Company's stockholders to approve the Extension Amendment will be held virtually on January 27, 2022 at 11:00 AM, Eastern Time.The purpose of the Extension Amendment is to allow LCAP more time to complete its previously announced business combination with MSP Recovery. Stockholders are not being asked to vote on the proposed business combination at this time. The Company's stockholders of record at the close of business on the record date, December 31, 2021, are entitled to vote the shares of common stock of LCAP owned by them at the Special Meeting. If the Extension Amendment is approved and the Extension is implemented, the Company, the Company's sponsor and/or any of its affiliates or designees will contribute to the Company's trust account an aggregate amount equal to $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension Amendment. Such contribution by the Company's sponsor and/or its affiliates or designees will be made as a loan that will not accrue interest and will be repayable to the Company's sponsor, or its respective designees upon the consummation of an initial business combination. The contribution will increase the pro rata portion of the funds available in the Company's trust account in the event of the consummation of an initial business combination or liquidation from approximately $10.00 per share to approximately $10.20 per share. If the Extension Amendment is not approved, the Company will be unable to consummate the proposed business combination with MSP and, in accordance with LCAP's charter, LCAP will be required to dissolve and liquidate the trust account by returning the then-remaining funds in such account to stockholders.

08:14 EST AIM announces results from Phase 1/2 study of of IP chemo-immunotherapy - AIM ImmunoTech announced the publication of positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer. The manuscript titled, "Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity" was published in the American Association for Cancer Research publication, Clinical Cancer Research. The Phase 1/2 study being conducted by the University of Pittsburgh School of Medicine is designed to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal, IP, cisplatin, IPC, with intravenous paclitaxel followed by peritoneal infusion of a chemokine modulatory regimen composed of a cocktail of IP rintatolimod and interferon-alpha for patients with advanced stage ovarian cancer at primary neoadjuvant setting. Thomas Equels, Chief Executive Officer of AIM commented, "We are very pleased with these results. Ampligen has demonstrated broad immunological effects and we believe has the potential to be a key component in the treatment of ovarian cancer. We are grateful to the University of Pittsburg School of Medicine and are excited to provide support for a larger Phase 2 study which we believe has the potential to provide hope for patients and their families, as well as drive significant shareholder value." Twelve patients were enrolled in Phase 1 portion of the trial and were treated with IP cisplatin, IP Ampligen, and oral celecoxib. Patients in cohorts 2, 3 and 4 also received IP IFNalpha at 2, 6 and 18 million units, respectively. The primary objectives of the study were to evaluate safety, identify Phase 2 recommended dose and characterize changes in the immune. Overall, the regimen was well tolerated, apart from the highest dose of IFNalpha. Most common toxicities for all grades were anemia, hypomagnesemia, hyponatremia, arthralgia, and fatigue. There was one grade 4 hypomagnesemia. Dose limiting toxicities of abdominal pain of grade 3 or more were noted in two patients who received 18MU IFNalpha. The Phase 2 recommended dose of IFNalpha was 6M units every 3 weeks. Median PFS was 8.4 months. Median overall survival was 30 months. Overall response rate was 55.6% and the disease control rate was 77.8%, consistent with the expected platinum-sensitive response.

08:13 EST Nordstrom jumps 7% in premarket trading as Kohl's fields takeover interest

08:13 EST Macy's jumps over 8% in premarket trading as Kohl's fields takeover interest

08:11 EST GeoPark announces first oil, gas discovery in Ecuador - GeoPark announced its first hydrocarbon discovery in the Perico block in the Oriente basin in Ecuador. The Jandaya 1 exploration well was drilled and completed to a total depth of 10,975 feet where a total of 70-80 feet vertical depth of potential hydrocarbon bearing reservoir was encountered in three formations, with the Hollin formation as the main target. To date, the operator has carried out production tests in the lower Hollin formation, showing a production rate of 750 barrels of oil per day of 28 degrees API and 0.8M standard cubic feet per day of gas, for a combined 890 barrels of oil equivalent per day with a 8% water cut, after five days of testing. The complete testing program is underway, and the operator plans to start production tests in the upper Hollin formation in the upcoming days. Additional testing and production history will be required to determine stabilized flow rates of the well and the extent of the reservoir. Oil production from Jandaya 1 is already being delivered to a nearby access point on Ecuador's main pipeline system for sale to export markets. GeoPark and its partner Frontera Energy Corporation are currently evaluating subsequent activities in the Jandaya field, including a potential development plan. The drilling rig in the Perico block is currently moving to the Tui exploration prospect, located 6 km south of the Jandaya 1 well, to be spudded in February 2022. Tui also has the Hollin formation as its main objective. Further exploration activities are budgeted to continue in Ecuador during 2022 in the Espejo Block with the acquisition of 60 square km of 3D seismic to be followed by the drilling of a first exploration well in the block, expected to spud in 2H2022.

08:10 EST Reneo Pharmaceuticals announces changes to board of directors - Reneo Pharmaceuticals (RPHM) announced changes to its Board of Directors. Paul Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics (HZNP), has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction with the appointment of Hoelscher, Kenneth Harrison, Partner at Novo Ventures, resigned from the Reneo Board of Directors. Reneo also announced that Lon Cardon, Ph.D. will not seek re-election to its Board of Directors at the upcoming 2022 annual meeting of shareholders. Dr. Cardon recently assumed the role of President and Chief Executive Officer of The Jackson Laboratory and due to institutional policy will be unable to serve on the Board beyond his current term.

08:08 EST Interra Copper reports Cathedral Main Zone drill results - Interra Copper announces further 2021 summer season drilling results from the Cathedral Area at its 20,600 hectare Thane Property, located on traditional territory of the Takla and Tsay Keh Dene First Nations in North-Central B.C. Results are from drill holes TH21-3, TH21-4, TH21-6, and TH21-12. TH21-3 and TH21-12 were designed to test the southern extent of a 600 square meter IP chargeability along line 5300N within the Cathedral Main zone. TH21-4 was drilled within the Cathedral South zone on the western extent of IP line 5200. TH21-6 was designed to test a broad, hidden, near surface 200 square meter IP chargeability anomaly approximately 350 meters to the east also on line 5300N. Drill holes intersected indicator low grade copper-gold mineralization. Anomalous mineralized intervals of significant copper, gold, silver or molybdenum include: TH21-3: 20.65m of 0.08% Copper from 20.10 to 40.75m hole depth. TH21-4: 17.30 m of 0.05% copper, 0.03 ppm gold, 0.2 ppm silver and 7.20 ppm molybdenum from 108.20 to 125.50 m hole depth and a 0.08 Copper Equivalent CuEq grade. TH21-6: 36.71 meters of indicator mineralization within an intercept from 120.0 m to 156.71m hole depth, containing 0.07% copper, 0.5 ppm silver and 5.0 ppm molybdenum and a "CuEq" grade of 0.09%. TH21-12: 5.00 meters of indicator mineralization within an intercept from 113.35m to 118.35m hole depth, containing 0.21% copper, 0.07 ppm gold, 0.6 ppm silver and 23.6 ppm molybdenum and a CuEq grade of 0.28%.

08:08 EST Amyris to acquire Menolabs, terms not disclosed - Amyris has agreed to exclusive terms to acquire the assets of MenoLabs, a women-founded company focused on addressing perimenopause and menopause symptoms. MenoLabs offers research-backed all-natural treatments of menopause symptoms. The menopause market was valued at around $15B in 2020 and is expected to reach approximately $23B by 2028.

08:06 EST CN Energy and Xujin Environmental Protection enter strategic cooperation - CN Energy announced a strategic cooperation between its subsidiary CN Energy Industrial and Xujin Environmental Protection. The two companies will cooperate in sharing technology, resources and expertise for their mutual benefits, as they create an integrated and optimized activated carbon sales business focused on revenue and profit growth opportunities in the hazardous waste and solid waste disposal businesses. Founded in 2016, Xujin Environmental Protection has been focused on growing its business in the hazardous waste treatment industry. The company has expertise in the regeneration of saturated activated carbon and the sales of recycled activated carbon.

08:06 EST SWM, ConvaTec enter long-term supply agreement - Schweitzer-Mauduit International (SWM) and ConvaTec (CNVVY) announce that they have entered into a multi-year supply agreement in conjunction with their amicable resolution of pending litigation between the companies. Terms of the settlement and the commercial agreement were not disclosed. John Petreanu, President - Scapa Healthcare commented, "We are pleased to restart this long-term commercial relationship with ConvaTec, a leader in advanced wound care and ostomy products. SWM's subsidiary Scapa Healthcare has a lengthy history of delivering superior service and high-quality products that have supported ConvaTec over the years, and we welcome this opportunity to move forward together with a renewed sense of partnership and collaboration."

08:04 EST AudioCodes names Dmitry Netis as Chief Strategy Officer - AudioCodes announced the appointment of Dmitry Netis as Chief Strategy Officer, effective immediately. Netis will report to Shabtai Adlersberg, President and CEO of the company. Netis joins AudioCodes having worked 25 years in the technology sector and after 15 years on Wall Street covering infrastructure and application companies in Unified Communications, Collaboration, Customer Experience markets, among other sectors. Most recently Netis worked as a managing director and an investment banker with Q Advisors, and as senior equity research analyst at Stephens, and William Blair & Company.

08:03 EST Apollo Global, Athene, BNP Paribas partner to launch Eliant Inventory Solutions - Apollo (APO) and its subsidiary Athene announce they have entered into a strategic relationship with BNP Paribas (BNPQY) to provide a dynamic new solutions platform for working capital and supply chain needs with the establishment of Eliant Inventory Solutions. The company said, "Eliant provides domestic and multinational companies with strategic and responsive inventory capital solutions to better optimize their supply chains and balance sheets, and buffer inventories. For companies, this can mean greater resiliency, fewer supply chain disruptions and more efficient working capital management. Eliant is structured to own inventory at an efficient cost of capital, with a technology platform to seamlessly manage high-volume and complex customer needs. Eliant launches with strong customer demand, marked by $1.3 billion in signed or awarded inventory programs with blue-chip customers." BNP Paribaswill provide debt and receivables financing as well as structuring advisory and referral services to Eliant. Athene will serve as the primary capital provider to Eliant, while Apollo will act as the investment manager, supporting an in-house team at Eliant that is delivering customized supply chain inventory solutions to customers across industries and geographies.

08:02 EST Lyell Immunopharma announces FDA clearance of IND for LYL132 - Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration, FDA, has cleared an Investigational New Drug, IND, application to initiate a Phase 1 clinical trial for LYL132, an investigational T-cell receptor, TCR, therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1, NY-ESO-1, that the company is developing in collaboration with GSK (GSK). "Clearance of the second IND incorporating Lyell's novel reprogramming technologies is another important milestone for Lyell, especially coming within a month of FDA clearance of an IND for LYL797, our lead CAR program," said Liz Homans, Chief Executive Officer of Lyell. "We are eager to start multiple clinical trials that utilize our technologies to assess the potential benefits for patients with solid tumor cancers and also remain on track for two additional INDs by the end of this year." The planned Phase 1 trial will assess LYL132 in patients with NY-ESO-1+ advanced synovial sarcoma or myxoid/round cell liposarcoma. Lyell will manufacture LYL132 in its LyFE Manufacturing Center and GSK will conduct the Phase 1 trial.

07:49 EST Digital Ally's Nobility Healthcare acquires billing company for $2.1M - Digital Ally announced that its new healthcare subsidiary, Nobility Healthcare, LLC, has acquired a third billing company with an annual revenue run rate of approximately $3.5M. This closely-held company was founded several years ago and provides revenue cycle management and other services for over 180 dental practices located throughout the United States. This acquisition represents a new vertical for Nobility Healthcare because the target's focuses on providing insurance claim reimbursement billing, verification, and related services to dentists and dental practices rather than medical providers, as is the case with the Nobility Healthcare's previous acquisitions. This latest purchase gives Nobility Healthcare an anticipated annual revenue run-rate of approximately $7.5M. The purchase price was $2,100,000 with approximately 64% paid in cash at the closing and the balance through an earn-out promissory note bearing interest at 3% annually payable over 37 months. The earnout note is subject to adjustment based on future revenues and client retention of the acquired company.

07:43 EST Crypto stocks down sharply pre-market as bitcoin falls to six-month lows - The price of bitcoin has extended last week's decline to $33,000 this morning - the lowest level in six months. Stocks levered to bitcoin prices are also down sharply in early pre-market session, with Bit Digital (BTBT) down 10.0%, Riot Blockchain (RIOT) down 11.3%, Marathon Digital (MARA) down 12.2%, and Coinbase Global (COIN) down 9.8%.

07:41 EST Kohl's shares surge 27% premarket as Acacia, Sycamore show takeover interest

07:37 EST Camping World adds $152,708,900 to existing stock repurchase program - Camping World Holdings announced that its Board of Directors has authorized an increase in its stock repurchase program after which $200,000,000 remains available for the repurchase of the Company's Class A common stock. The Board of Directors has authorized an increase in the Company's $225,000,000 stock repurchase program originally approved on October 30, 2020, to allow for the repurchase of an additional $152,708,900 of its Class A common stock, effective immediately, resulting in approximately $200,000,000 remaining available for such repurchases. The Board of Directors also extended the expiration of the repurchase authorization to December 31, 2025.

07:36 EST Arbutus Biopharma announces 2022 corporate objectives, financial update - Arbutus Biopharma announced its 2022 corporate objectives and provided a financial update. Summary of 2022 Anticipated Key Milestones: HBV Franchise: Announce preliminary AB-729 data in the second half of 2022 from the three on-going Phase 2a proof-of-concept clinical trials in patients with chronic hepatitis B infection. Initiate a triple combination Phase 2a proof-of-concept clinical trial in the first half of 2022 to evaluate AB-729, combined with VTP-300, Vaccitech's therapeutic vaccine, and a NA. Present at a medical conference the data from the Phase 1a/1b clinical trial of AB-729. Announce data from its Phase 1a/1b clinical trial evaluating AB-836 in patients with chronic HBV in the first half of 2022. Complete IND-enabling studies with its oral PD-L1 inhibitor compound, AB-101, in the second half of 2022. Complete IND-enabling studies for AB-161 in the second half of 2022. COVID-19 & Pan-Coronavirus Franchise: Nominate a candidate that inhibits the SARS-CoV-2 nsp5 main protease in the first half of 2022 and advance into IND-enabling studies. Continue lead optimization activities for an Nsp12 viral polymerase candidate. Other Opportunities: Explore potential oncology applications for internal PD-L1 portfolio. Financial Update: The company had cash, cash equivalents and investments in marketable securities totaling $191M as of December 31, 2021. This amount does not include a $40M upfront payment and $15M of proceeds resulting from the sale of common stock to Qilu Pharmaceutical. These amounts were received in January 2022. The company expect its net cash burn to range from $90M-$95M in 2022.

07:34 EST Azorra places order for 20 Embraer E2 aircraft valued at $3.9B - Azorra has signed an agreement with Embraer to acquire 20 new E2 family aircraft, plus a further 30 purchase rights. This flexible deal enables Azorra to acquire E190-E2 or E195-E2 aircraft. At list prices, the order is valued at $3.9B. Azorra is a Florida-based aircraft leasing company specialising in executive, regional and crossover aircraft. Deliveries will begin in 2023, adding a further 20 Embraer aircraft to the 21 already in Azorra's existing and committed portfolio.

07:32 EST Missfresh says sales of 3R products on platform rose over 300% vs. 2020 - Missfresh announced its sales growth performance for Ready-to-Cook, Ready-to-Heat, and Ready-to-Eat products, referred to as 3R products, and its plans to further expand this category. In 2021, sales of 3R products on Missfresh's platform increased more than 300% compared with 2020, with a gross margin for these products at least 15% above the platform's average. By the end of 2021, more than 40% of Missfresh customers have added 3R products into their shopping baskets and the repurchase rate for paid membership users was close to 70%. The strong sales of this category demonstrate consumers' growing appetite for ready meals, and a notable food consumption trend in China for 2022. Catherine Chen, CFO, commented, "As the consumer awareness of the product category and popularity of ready meals skyrocketed in the past two years, Missfresh has invested in developing its own in-house brands of 3R products. We currently offer more than 800 SKUs of 3R meals, including 100+ SKU of Missfresh's in-house premium line of ready meals. Missfresh plans to continue expanding its offerings of ready meals to include one-bowl meals for solo diners, hot pot dishes and home-cooked fare with mass appeal. We expect 2022 sales growth to top 2021's figures. We see the ready meals offerings not just as a way to meet the 'consumption upgrade' trend among our platform users, but also an important category to optimize our gross margins and improve profitability. We are confident that ready meals are poised to become an important driver for the Company's operational efficiency."

07:19 EST Ocugen announces Jagota as SVP, Regulatory Affairs, compliance, safety - Ocugen (OCGN) announced the appointment of Nirdosh Jagota, Ph.D., as Senior Vice President, SVP, Regulatory Affairs, compliance and safety. "He'll be responsible for ensuring the global strategy, development and execution of regulatory activities for the company's pipeline, including gene therapies and vaccines, are aligned with local and international registration requirements," the company said. He will serve as a member of Ocugen's management team, reporting directly to the CEO. Prior to joining Ocugen, Jagota was Executive Vice President and Chief Regulatory Officer of Arcturus Therapeutics (ARCT).

07:17 EST Connect Biopharma presents data, analyses from Phase 2b trail of CBP-201 - Connect Biopharma announced that data from the global Phase 2b clinical trial of CBP-201 administered subcutaneously, SC, to adult patients with moderate-to-severe atopic dermatitis, AD, will be presented in two abstracts and posters at the Maui Derm Conference that begins today, January 24th, and ends January 28th. The abstracts and posters will expand on the results reported by the Company on January 5, 2022. The abstracts and posters will also provide detail of the analyses performed by the Company of patients within the trial with higher baseline disease severity that more closely approaches the disease severity in Phase 3 trials of the approved IL-4R agent. "These analyses consistently demonstrate increased efficacy as baseline disease severity increases, indicating that CBP-201 has the potential for a highly competitive efficacy and safety profile that includes a differentiated Q4W dosing schedule," the company said. Poster Presentation Details: Title: Efficacy and Safety of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase 2b, Randomized, Double-blind, Placebo-controlled Trial. Title: The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial.

07:16 EST CynergisTek announces new six-figure cybersecurity consulting contract - CynergisTek announces it has signed another new six-figure engagement, this time to provide a security risk assessment with remediation support for a well-known philanthropic non-profit located on the west coast. Through this engagement, CynergisTek will be able to help the organization assess its current cybersecurity programs and defenses, provide advisory and mitigation support building organizational resilience associated with the risks of today, and validate that their programs are ready to stand up to the current threat landscape. "We are seeing momentum in the market and continued demand for both our consulting and managed services offerings from new and existing clients," says Mac McMillan, CEO and President of CynergisTek. "Our goal is both short and long term growth through partnerships and new contracts such as this one are key components of our go-forward strategy."

07:15 EST Gilat Satellite, Intelsat expand strategic partnership in commercial aviation - Gilat Satellite Networks announced that the company is expanding its strategic partnership in commercial aviation with Intelsat, operator of an integrated satellite and terrestrial network headquartered in McLean, Virginia. To enable the expansion of commercial and business aviation services in Asia, Intelsat will be using Gilat's SkyEdge II-c system, which, in addition to providing in-flight connectivity, is designed to deliver fixed and mobility services for maritime and land-mobility, as well. "We value our strong, continuing partnership with Intelsat, and are looking forward to seeing the expanded service coverage in Asia, supporting Intelsat's efforts to deliver in-flight connectivity internationally," said Amir Yafe, VP of Mobility & Global Accounts at Gilat. "This network expansion is a testament to the strength of Gilat technology for IFC. The expanded network will address the increased demand for internet connectivity in the commercial and business aviation market on a global scale and, with the current recovery of global aviation, the timing couldn't be better."

07:14 EST Else Nutrition announces uplisting to Toronto Stock Exchange - Else Nutrition Holdings is pleased to announce that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange.

07:14 EST Strategic Lease Partners buys $780M in net leased properties in Q421 for KKR - Strategic Lease Partners closed six transactions in the fourth quarter of 2021 for a total of $780m. SLP is working closely with KKR's real estate, credit and capital markets teams to underwrite a wide range of mission-critical properties and deliver customized sale-leaseback solutions for a group of high quality corporate and sponsor-backed tenants. The platform is initially targeting to acquire more than $3b in assets, primarily capitalized through KKR's credit and real estate funds. "SLP has built great momentum in its first few months of operation," said Peter Sundheim, Managing Director on KKR's real estate team. "We are delighted with the exceptional quality and diversification of the assets SLP has acquired for our NNN portfolio." Michelle Hour, Director on KKR's credit team added, "SLP's ability to invest in deals of all sizes and to utilize its access to the KKR platform to deliver strong underwriting with speed and certainty is clearly resonating with sponsors and corporate tenants seeking to unlock the value of their real estate." The six transactions SLP closed last quarter followed the platform's launch in August 2021 and consisted primarily of mission critical industrial assets, with a focus on sale-leasebacks for private equity-backed companies with durable business models. The transactions ranged in size from under $15 million for an individual property to over $ million for a portfolio and included both domestic and cross-border portfolios. SLP's acquisitions comprised 31 individual assets across nearly 5.4 million square feet with a weighted average lease term of over 16 years, while over half of the portfolio holds LEED designation. SLP's Q4 2021 acquisitions include some of the the following transactions: A 20-property, multi-state manufacturing and distribution portfolio that is majority LEED certified and leased to a global beverage brand on a long-term basis A four-building manufacturing portfolio across major Canadian and United States markets leased to a leading North American retail and food services company.

07:13 EST HCW announces Masonic Cancer Center receives FDA clearance for trial on HCW9218 - HCW Biologics announced that the Masonic Cancer Center, University of Minnesota was cleared by the U.S. Food and Drug Administration, FDA, to proceed to evaluate the Company's lead drug candidate, HCW9218, in a Phase 1 clinical trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. Hing Wong, Ph.D., Founder and CEO of HCW Biologics, stated, "HCW Biologics is honored to have the Masonic Cancer Center as the sponsor for the second clinical trial to evaluate HCW9218 in difficult-to-treat cancers. This is an important milestone for HCW Biologics and our efforts to advance the development of potentially groundbreaking immunotherapeutic candidates for cancer and other age-related diseases. We have demonstrated that HCW9218 can augment the anti-tumor activities and lessen the side effects of chemotherapies by reducing the therapy-induced senescent cells in preclinical animal models."

07:11 EST Tango Therapeutics announces clearance of TNG908 IND, pipeline progress - Tango Therapeutics announced progress updates across its pipeline and recent corporate highlights. Pipeline Progress Updates: The U.S. Food and Drug Administration, FDA, has cleared the Investigational New Drug, IND, application for the Company's lead program, TNG908. Tango expects to initiate a Phase 1/2 clinical trial in the first half of 2022, with preliminary safety and efficacy data expected in the first half of 2023. Target 3, an undisclosed synthetic lethal target, reverses the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations. In syngeneic mice, Target 3 inhibition, in combination with an anti-PD1 antibody, resulted in complete regressions in all treated mice, and the induction of immune memory against re-implantation of tumors in the majority. Tango expects to advance a development candidate in the first half of 2022 and file an IND in 2023. Tango anticipates advancing a development candidate for their ubiquitin-specific protease 1, USP1, program, a synthetic lethal target for BRCA1-mutant breast, ovarian and prostate cancer, in the second half of 2022. Tango expects to advance a development candidate in the second half of 2022 and file an IND in 2023. Tango is announcing the addition of Dr. Michael Palmieri to the leadership team as Head of Chemistry, Manufacturing, & Controls, CMC, where he will be responsible for leading all CMC-related activities for the Company, including process chemistry, drug substance, drug product, analytical, and formulation activities.

07:10 EST CytoSorbents' drug removal technology shows efficacy in new publication - CytoSorbents highlighted a new publication in the peer-reviewed journal, Annals of Thoracic and Cardiovascular Surgery, which reported on the use of intraoperative hemoadsorption using CytoSorbents' technology to reduce perioperative bleeding complications in patients with acute type A aortic dissection, a life-threatening condition with a mortality rate of 1-2% per hour, who were either on the direct oral anticoagulant rivaroxaban or the antiplatelet drug ticagrelor at the time of urgent on-pump cardiac surgery. CytoSorb is approved in the EU and distributed in 67 countries worldwide. Although the operative techniques and duration on cardiopulmonary bypass were similar between the two groups, total operation time was significantly shorter in the hemoadsorption group, presumably due to less time required to achieve hemostasis at the end of the operation. Intraoperative hemoadsorption vs. without was associated with favorable clinical outcomes following urgent type A aortic dissection surgery. The clinical benefits translated to shorter median ICU length of stay in patients treated with hemoadsorption compared to those without.

07:08 EST BioLineRx completes enrollment in Phase Phase 1/2a study of AGI-134 - BioLineRx announced that the company has completed enrollment of the Phase 1/2a study of its innovative intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors. Results of AGI-134's safety and proof of mechanism are anticipated in the first half of 2022.

07:07 EST Enerflex, Exterran announces business combination in $735M all-share transaction - Enerflex (ENRFF) and Exterran Corporation (EXTN) announced a business combination to create a premier integrated global provider of energy infrastructure. The company will operate as Enerflex Ltd. and will remain headquartered in Calgary, Alberta, Canada. Through greater scale and efficiencies, the transaction will strengthen Enerflex's ability to serve customers in key natural gas, water, and energy transition markets, while enhancing shareholder value through sustainable improvements in profitability and cash flow generation. The companies will combine in an all-share transaction pursuant to which Enerflex will acquire all of the outstanding common stock of Exterran on the basis of 1.021 Enerflex common shares for each outstanding share of common stock of Exterran, resulting in approximately 124 million Enerflex common shares outstanding upon closing, representing an implied combined enterprise value of approximately US$1.5 billion. The transaction value for Exterran is approximately US$735 million, which represents an 18% premium to Exterran's enterprise value as at January 21, 2022. The transaction value paid for Exterran implies an EV/2022E Adjusted EBITDA of 3.6x and Price/2022E Cash Flow of 1.9x, including synergies, respectively. Upon closing of the Transaction, Enerflex and Exterran shareholders will respectively own approximately 72.5% and 27.5% of the total Enerflex common shares outstanding. Enerflex will continue to trade on the Toronto Stock Exchange and intends to apply to either the New York Stock Exchange or the NASDAQ exchange for the listing of Enerflex common shares to be effective upon Transaction close. Expect to realize at least US$40 million of annual run-rate synergies within 12 to 18 months after closing through overhead savings and operating efficiencies. Expected to approximately double Adjusted EBITDA and be over 50% accretive to cash flow per share and approximately 50% accretive to earnings per share, for Enerflex shareholders. Enhanced scale with pro forma 2023E Adjusted EBITDA of US$360 million to 400 million, inclusive of synergies. Meaningful excess free cash flow beginning in 2023 that supports debt reduction, shareholder returns, and continued growth. After close, Enerflex expects to maintain its quarterly dividend of CAD$0.025 per common share. The combined entity will benefit from a capital structure that provides ample liquidity. In conjunction with the Transaction, Enerflex has entered into a binding agreement with the Royal Bank of Canada to provide Enerflex with a fully committed financing consisting of a US$600 million 3-year revolving credit facility and a US$925 million 5-year bridge loan facility. The bridge loan will provide financing to backstop an anticipated issuance of new debt securities prior to closing of the Transaction. The committed financing is sufficient to fully repay existing Enerflex and Exterran notes and revolving credit facilities and support putting in place a new capital structure, provide for capital expenditures and other ordinary course capital needs, and provide significant liquidity for the pro forma business. The new revolving credit facility will be subject to a bank-adjusted total net debt to EBITDA covenant of 4.5x, stepping down to 4.0x by the fourth quarter of 2023. One Exterran director will be appointed to Enerflex's Board of Directors at closing. Mr. Marc Rossiter will continue to serve as Enerflex's President and Chief Executive Officer and a member of the Board of Directors of Enerflex and will oversee all aspects of integration. Mr. Sanjay Bishnoi will continue to serve as Enerflex's Chief Financial Officer. Enerflex's Executive Management Team will continue to serve in their current roles. The Transaction is expected to close in the second or third quarter of 2022, subject to, among other things: the approval of the Transaction by Exterran stockholders; the approval by Enerflex shareholders of the issuance of Enerflex common shares pursuant to TSX requirements in connection with the Transaction; regulatory approvals; and other customary closing conditions, including those of the TSX and the NYSE or NASDAQ, as applicable. The Boards of Directors of Enerflex and Exterran have each unanimously approved the Transaction and recommend that their respective shareholders vote in favour of the Transaction. All of the funds managed by Chai Trust Company, LLC that own common stock of Exterran and all of Exterran's directors and officers have entered into voting agreements with Enerflex pursuant to which they have agreed to vote their respective shares in favour of the Transaction at the meeting of Exterran shareholders. All of the directors and officers of Enerflex have entered into voting agreements with Exterran pursuant to which they have agreed to vote their respective Enerflex common shares in favour of the issuance of Enerflex common shares pursuant to the Transaction at the meeting of Enerflex shareholders.

07:06 EST Ionis Pharmaceuticals: Eplontersen gets orphan drug designation from U.S. FDA - Ionis Pharmaceuticals announced that the U.S. FDA has granted orphan drug designation to eplontersen, an investigational antisense medicine for the treatment of people living with transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition. Orphan drug designation is granted by the FDA to drugs and biologics intended for treatment, prevention or diagnosis of a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of designation.

07:05 EST Lantern Pharma's LP-184 designated Rare Pediatric Disease and Orphan Drug - Lantern Pharma's drug candidate LP-184 has been granted both Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for the treatment of pediatric patients with ATRT. LP-184 is being pursued as a potential new therapy across a range of genetically defined solid tumors, including pancreatic cancer, GBM - Glioblastoma Multiforme - and ATRT - Atypical Teratoid Rhabdoid Tumor -. ATRTs are very aggressive childhood malignancies of the central nervous system. LP-184 is being developed for multiple targeted oncology indications. Lantern Pharma intends to further advance LP-184 as a new, potent treatment option in genetically defined subsets of patient populations in areas of high unmet clinical need, including pancreatic cancers, GBM, and other cancers that are DNA damage repair deficient.

07:03 EST Talos Energy sees Q4 average daily production 67,500-69,000 mboepd - Average daily production between 67.5 and 69.0 thousand barrels of oil equivalent, or mboepd in Q4, representing a new quarterly record. Fourth quarter production was above the previously indicated range due to better than expected uptime and was approximately 69% oil and 77% liquids. Sees Q4 capital expenditures for Q4 between $63M-$68M putting the company near the low end of its previously issued full year capital guidance range. Talos president and CEO Timothy Duncan commented: "It was an outstanding fourth quarter, capping a record year for Talos with strong production, attractive oil-weighted margins and robust free cash flow. The team finished the year strong and worked hard to manage the portfolio at an extremely efficient level. We look forward to providing more details on the quarter and the full year results in our earnings release. We are excited about the strength of our business as we exit 2021. Our 2022 plan will continue to focus on generating meaningful free cash flow, which will allow us to continue to deleverage the balance sheet and increase liquidity. We also will expose the business to more high impact drilling projects in 2022. Moreover, we will be expanding our budget in carbon capture and sequestration to build upon the early wins achieved in that business. This framework best positions Talos to build long term shareholder value as a differentiated conventional, offshore-focused firm. We will maintain a strong balance sheet, invest in unique catalysts, such as our Puma West discovery and carbon capture business, and continue to actively evaluate an array of transformational M&A opportunities. Fiscal year 2022 will be an exciting year for Talos and we look forward to providing more updates very soon."

07:03 EST Viking Therapeutics announces clinical hold on Phase 1b trial of VK0214 - Viking Therapeutics announced that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy has been placed on clinical hold by the United States FDA. The FDA has requested an additional preclinical study prior to continuing the Phase 1b study of VK0214 in X-ALD. The request is not due to any findings from ongoing or previously completed studies. The company expects to provide the information to the FDA in the second quarter. The company was recently informed that the FDA considers the ongoing trial to be a Phase 2 trial rather than a Phase 1b. As a Phase 2 trial a rodent genotoxicity study is required prior to continuation. The company had planned to conduct this study prior to Phase 2 and will now accelerate its execution. While a short-term delay is anticipated, the company does not expect the long-term development timeline for VK0214 to be significantly impacted. "We look forward to providing the FDA with the requested information in a timely fashion. The current request is in keeping with industry guidance for Phase 2 studies and is not based on data from previously submitted or ongoing studies. We are confident in the overall safety and potential efficacy profile of VK0214 and expect to submit a response with a goal to resume dosing in the study later this year," said Brian Lian, Ph.D., CEO of Viking Therapeutics.

07:01 EST Karyopharm receives FDA orphan designation for eltanexor - Karyopharm Therapeutics announced that the U.S. FDA has granted orphan drug designation for eltanexor, a novel oral, Selective Inhibitor of Nuclear Export compound, for the treatment of myelodysplastic syndromes. MDS are a group of diseases characterized by ineffective production of the components of the blood due to poor bone marrow function with a risk of progression to acute myeloid leukemia.

06:57 EST Halliburton CEO says 'excited about the accelerating multi-year upcycle' - "I am pleased with our solid execution in the fourth quarter and for the full year. Both operating divisions experienced revenue growth in the international and North America markets. Our Completion and Production division delivered solid mid-teens margins, and our Drilling and Evaluation division margins surprised to the upside," commented Jeff Miller, Chairman, President and CEO. "Today's announcements of the dividend increase and debt retirement demonstrate my confidence in our business, customers, employees, and value proposition. I am excited about the accelerating multi-year upcycle. I expect the macro industry environment to remain supportive and the international and North America markets to continue their simultaneous growth. Halliburton uniquely benefits from this constructive environment. Our value proposition works, we have the right strategies for both international and North America markets, we are leaders in digital and automation, and we drive capital efficiency while advancing a sustainable energy future. I fully expect that Halliburton will accelerate cash flow generation, strengthen our balance sheet, and increase cash returns to shareholders in this upcycle," concluded Miller.

06:51 EST ANI Pharmaceuticals announces commercial availability of Purified Cortrophin Gel - ANI Pharmaceuticals announced the U.S. commercial availability of Purified Cortrophin Gel 80 U/mL. The commercial launch of Cortrophin Gel, an adrenocorticotropic hormone, also known as purified corticotropin, is being led by ANI's recently established rare disease business unit. Cortrophin Gel is indicated for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis, and excess urinary protein due to nephrotic syndrome. For full list of indications, please see below.

06:47 EST Merck says FDA issues CRL regarding NDA for gefapixant - Merck announced that the U.S. FDA has issued a Complete Response Letter regarding Merck's New Drug Application for gefapixant, the investigational, non-narcotic, orally administered selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough or unexplained chronic cough in adults. In March 2021, Merck announced that the FDA accepted the company's NDA for gefapixant. In the CRL, the FDA requested additional information related to measurement of efficacy. The CRL was not related to the safety of gefapixant. Merck is reviewing the letter and will meet with the agency to discuss next steps. "We remain committed to advancing gefapixant for patients with refractory or unexplained chronic cough and will work with the FDA to address the agency's feedback," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "We believe there is a significant unmet need to help patients manage their chronic cough, as there are no available treatment options indicated in the U.S. specifically for this condition."

06:46 EST Halliburton raises quarterly dividend to 12c per share - Payable on March 23 to shareholders of record at the close of business on March 2.

06:27 EST Wisk Aero secures $450M in funding from Boeing - Wisk, an Advanced Air Mobility company and developer of the first all-electric, self-flying air taxi in the U.S., has secured $450M in funding from The Boeing Company, the company said in a statement. This investment will further advance the development of Wisk's 6th generation eVTOL aircraft, a first-ever candidate for certification of an autonomous, all-electric, passenger-carrying aircraft in the U.S. The funding will also support the company as it enters an intensive growth phase over the next year, its preparations for the launch of scale manufacturing, and the company's Go-to-Market efforts, it said. Gary Gysin, CEO of Wisk said: "Wisk is extremely well-positioned to deliver on our long-term strategy and commitment to safe, everyday flight for everyone. We are incredibly fortunate to have Boeing as not only an investor but a strategic partner, which provides us with access to a breadth of resources, industry-leading expertise, a global reach, extensive certification experience, and more. As we enter this next stage of our growth, this additional funding provides us with capital while allowing us to remain focused on our core business and our number one priority, safety." Reference Link

06:11 EST Parsons elects Carey Smith as Chairwoman - The board of directors of Parsons has unanimously elected Carey Smith as chairwoman, effective April 14. Smith will serve as chairwoman, president, and CEO. She succeeds Charles "Chuck" Harrington, who currently serves as executive chairman and will retire when his current term on the board of directors expires on April 14, following 40 years with the company. The board also elected Steven Leer to serve as lead independent director effective April 14, succeeding James "Jim" McGovern, who has served as a director since joining the Parsons' board in 2005 and currently serves as lead independent director.

06:05 EST Parsons elects Carey Smith as Chairwoman - The board of directors of Parsons has unanimously elected Carey mith as chairwoman, effective April 14. Smith will serve as chairwoman, president, and CEO. She succeeds Charles "Chuck" Harrington, who currently serves as executive chairman and will retire when his current term on the board of directors expires on April 14, following 40 years with the company. The board also elected Steven Leer to serve as lead independent director effective April 14, succeeding James "Jim" McGovern, who has served as a director since joining the Parsons' board in 2005 and currently serves as lead independent director.

06:03 EST MediWound says Phase 2 study of EscharEx met primary endpoint - MediWound announced positive topline results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers. The study met its primary endpoint, demonstrating that patients treated with EscharEx had a statistically significant higher incidence of complete debridement compared to the gel vehicle, with a p-value of 0.004. The study randomized 120 patients, of which 119 patients were treated by either EscharEx, a gel vehicle, or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement. The study met its primary endpoint with high degree of statistical significance. Patients treated with EscharEx demonstrated a higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to patients treated with gel vehicle-EscharEx: 63% vs. gel vehicle: 30%. After adjusting for pre-specified covariates ascribed to patient baseline characteristics, wound size and age, regions, and sites, EscharEx efficacy superiority remained statistically significant compared to gel vehicle. Incidence of complete debridement of the non-surgical standard-of-care arm, during the same 14-day measurement period, was 13%. In addition, the Independent Data Monitoring Committee reviewed the data of all patients treated and no safety concerns were identified in the study population. EscharEx was well-tolerated and overall safety was comparable between the arms. No differences were found in reported adverse events and no serious adverse event was related to study treatment. Patient baseline characteristics were comparable across all study arms.

05:48 EST Buyer consortium announces $25 per share offer to acquire Hollysys - Recco Control Technology and Dazheng Group, as certain members of the buyer consortium, announced that, on December 3, 2021, the consortium submitted a non-binding proposal to acquire Hollysys in an all-cash transaction via a negotiated merger and today sent a letter to the board of directors of the company reiterating the proposal and requesting to commence due diligence and negotiation processes with the buyer consortium. Under the terms of the proposed acquisition, Hollysys shareholders would receive $25 per Hollysys share in cash, representing a 69.4% premium over Hollysys' closing share price of $14.76 on January 21. The consortium's offer also represents a premium of 75.5% over the volume-weighted average closing share price during the 30 trading days prior to January 22, and a premium of 51.7% over the volume-weighted average closing share price during the 180 trading days prior to January 22.

05:43 EST Philips expects to start year with comparable sales decline - The company said, "Based on good customer demand and our growing order book, we expect to resume our growth and margin expansion trajectory in the course of 2022. In the short term, however, we continue to see significant volatility and headwinds related to COVID-19 and supply chain challenges, despite our ongoing mitigation efforts. Due to this, the Respironics field action and the 9% comparable sales growth in Q1 2021, we expect to start the year with a comparable sales decline, followed by a recovery and strong second half of the year. For the full year, we target to deliver 5-6% comparable sales growth excluding Sleep & Respiratory Care. For the Group, we target 3-5% comparable sales growth and a 40-90 basis-points improvement in Adjusted EBITA margin."

05:29 EST Adtalem Global Education to divest Financial Services segment for $1B in cash - Adtalem Global Education announced it has entered into a definitive agreement to sell its Financial Services segment, which includes ACAMS, Becker Professional Education and OnCourse Learning, to a consortium of Wendel Group and Colibri Group in an all cash transaction for $1B. The transaction is expected to close in Q3, subject to customary closing conditions. The company will begin reporting the financial services segment as a held for sale and discontinued operation in its Q2 earnings report.

05:15 EST BeiGene announces RATIONALE 305 trial meets primary endpoint - BeiGene announced findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction, or G/GEJ, adenocarcinoma. At the interim analysis, tislelizumab in combination with chemotherapy met the primary endpoint of overall survival, or OS, in patients with PD-L1 expression, with additional follow-up needed to assess OS benefits in the intention-to-treat, or ITT, population. The safety profile of tislelizumab was consistent with that observed in previous trials, with no new safety signals identified with the addition of chemotherapy. RATIONALE 305 is a randomized, double-blind, placebo-controlled global Phase 3 trial comparing the efficacy and safety of tislelizumab combined with platinum and fluoropyrimidine chemotherapy and placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic G/GEJ adenocarcinoma. The primary endpoint of the trial is OS. Secondary endpoints include progression-free survival, or PFS, overall response rate, or ORR, duration of response, or DoR, and safety. A total of 997 patients from 13 countries and regions globally, including close to 50% from outside of China, were enrolled and randomized 1:1 to receive either tislelizumab and chemotherapy or placebo and chemotherapy.

05:10 EST Four Seasons Education receives noncompliance notification from NYSE - Four Seasons Education announced that it has received a letter from the New York Stock Exchange, notifying Four Seasons Education that it is below compliance standards due to the trading price of Four Seasons Education's American depositary shares.

05:02 EST Pfizer, Opko receive Complete Response Letter from FDA for somatrogon - Pfizer PFE) and Opko Health (OPK) announced Friday that the Food and Drug Administration issued a Complete Response Letter for the Biologics License Application for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency in pediatric patients. Pfizer said it is " evaluating the FDA's comments and will work with the agency to determine an appropriate path forward." Added Brenda Cooperstone, MD, Chief Development Officer, Rare Disease, Pfizer Global Product Development: "We remain confident in the potential treatment benefits that somatrogon has to offer patients around the world. We will work closely with the FDA to determine the best path forward to bring this important once-weekly treatment option to pediatric growth hormone deficiency patients and their families." In 2014, Pfizer and Opko entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of growth hormone deficiency . Under the agreement, Opko is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product for GHD.